6:25 PM
 | 
Nov 15, 2013
 |  BC Extra  |  Company News

Pfizer breaks off German pricing talks, withdraws Bosulif

Pfizer Inc. (NYSE:PFE) broke off pricing negotiations with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) for Bosulif bosutinib and said it will no longer market the Orphan cancer drug in Germany. Pfizer said there was...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >